A Second-Generation Nanoluc-IL27 Fusion Cytokine for Targeted-Gene-Therapy Applications
Open Access
- 16 February 2022
- journal article
- research article
- Published by MDPI AG in Bioengineering
- Vol. 9 (2) , 77
Abstract
An emerging approach in treating skeletal malignancies utilizes osteoimmunology to investigate new multifunctional immune-stimulatory agents that can simultaneously combat tumor growth and promote bone repair. We have hypothesized that cytokine Interleukin-27 (IL-27) is an excellent candidate biologic to help rebalance the prostate tumor cells and bone cell environment. In this work, we examined the proof of principle for a short, secreted luciferase (Nanoluc or Nluc) fusion with IL-27 to produce a novel cytokine-based biologic (Nluc-27), whereby we examined its efficacy in vitro in reducing prostate tumor growth and rebalancing bone cell proliferation and differentiation. This work demonstrates the targeting and anti-tumor efficacy of the Nluc-27 fusion cytokine in cancer and bone cell models. The fusion cytokine is detectable in conditioned media, and bioactive in different cell systems. This novel Nluc-27 cytokine will allow flexible incorporation of other targeting domains and may serve as flexible tool to augment IL-27′s bioactivity and reengineer its efficacy against prostate tumor or bone cells, and may prove applicable to several other cell types for targeted gene therapy applications.Keywords
Funding Information
- National Institutes of Health (CA196947, AR069079, CA196947S1, UL1TR002529)
This publication has 23 references indexed in Scilit:
- Interleukin‐27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitroJournal of Cellular Physiology, 2012
- Sonoporation Delivery of Interleukin-27 Gene Therapy Efficiently Reduces Prostate Tumor Cell Growth In VivoHuman Gene Therapy, 2011
- A 99mTc-labeled dual-domain cytokine ligand for imaging of inflammationNuclear Medicine and Biology, 2011
- A role for IL-27p28 as an antagonist of gp130-mediated signalingNature Immunology, 2010
- IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive TumorsThe Journal of Immunology, 2010
- Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitroBone, 2007
- Interleukin-23 and Interleukin-27 Exert Quite Different Antitumor and Vaccine Effects on Poorly Immunogenic MelanomaCancer Research, 2006
- A Novel Peptide Specifically Binding to Interleukin-6 Receptor (gp80) Inhibits Angiogenesis and Tumor GrowthCancer Research, 2005
- Distinct Phases of Coordinated Early and Late Gene Expression in Growth Plate Chondrocytes in Relationship to Cell Proliferation, Matrix Assembly, Remodeling, and Cell DifferentiationJournal of Bone and Mineral Research, 2003
- THE DEVELOPING ROLE OF CYTOKINES FOR IMAGING INFLAMMATION AND INFECTIONCytokine, 2000